JP2019504122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504122A5 JP2019504122A5 JP2018557190A JP2018557190A JP2019504122A5 JP 2019504122 A5 JP2019504122 A5 JP 2019504122A5 JP 2018557190 A JP2018557190 A JP 2018557190A JP 2018557190 A JP2018557190 A JP 2018557190A JP 2019504122 A5 JP2019504122 A5 JP 2019504122A5
- Authority
- JP
- Japan
- Prior art keywords
- defensin
- seq
- hbd2
- subject
- defensins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000018568 alpha-Defensin Human genes 0.000 claims 18
- 108050007802 alpha-defensin Proteins 0.000 claims 18
- 108050002883 beta-defensin Proteins 0.000 claims 17
- 102000012265 beta-defensin Human genes 0.000 claims 17
- 238000011282 treatment Methods 0.000 claims 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- 244000005709 gut microbiome Species 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 241000272517 Anseriformes Species 0.000 claims 2
- 102100037437 Beta-defensin 1 Human genes 0.000 claims 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 2
- 102000000541 Defensins Human genes 0.000 claims 2
- 108010002069 Defensins Proteins 0.000 claims 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 claims 2
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229940015047 chorionic gonadotropin Drugs 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 244000144972 livestock Species 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 241000731710 Allobaculum Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 241000272201 Columbiformes Species 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 claims 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 108010019598 Liraglutide Proteins 0.000 claims 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010027525 Microalbuminuria Diseases 0.000 claims 1
- 241000736262 Microbiota Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 241000286209 Phasianidae Species 0.000 claims 1
- 241000425347 Phyla <beetle> Species 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 235000013330 chicken meat Nutrition 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 108091005995 glycated hemoglobin Proteins 0.000 claims 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical group C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229960004717 insulin aspart Drugs 0.000 claims 1
- 108010050259 insulin degludec Proteins 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 229960002869 insulin glargine Drugs 0.000 claims 1
- 229960002068 insulin lispro Drugs 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 229960002701 liraglutide Drugs 0.000 claims 1
- 108010004367 lixisenatide Proteins 0.000 claims 1
- 229960001093 lixisenatide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims 1
- 125000001151 peptidyl group Chemical group 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 235000020989 red meat Nutrition 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670041 | 2016-01-26 | ||
| DKPA201670041 | 2016-01-26 | ||
| DKPA201670483 | 2016-07-01 | ||
| DKPA201670483 | 2016-07-01 | ||
| PCT/DK2017/050017 WO2017129195A1 (en) | 2016-01-26 | 2017-01-26 | Methods for modulating intestinal microbiota |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504122A JP2019504122A (ja) | 2019-02-14 |
| JP2019504122A5 true JP2019504122A5 (enExample) | 2020-12-24 |
| JP6890135B2 JP6890135B2 (ja) | 2021-06-18 |
Family
ID=58056942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557190A Expired - Fee Related JP6890135B2 (ja) | 2016-01-26 | 2017-01-26 | 腸内微生物叢を調節するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190111107A1 (enExample) |
| EP (1) | EP3407905B1 (enExample) |
| JP (1) | JP6890135B2 (enExample) |
| KR (1) | KR20180121489A (enExample) |
| CN (1) | CN108778309A (enExample) |
| AU (1) | AU2017212534A1 (enExample) |
| BR (1) | BR112018015170A2 (enExample) |
| CA (1) | CA3012711A1 (enExample) |
| ES (1) | ES2871117T3 (enExample) |
| MX (1) | MX2018009100A (enExample) |
| RU (1) | RU2738265C2 (enExample) |
| SG (1) | SG11201805954WA (enExample) |
| WO (1) | WO2017129195A1 (enExample) |
| ZA (1) | ZA201804515B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2740913C2 (ru) | 2016-04-29 | 2021-01-21 | Дефенсин Терапьютикс Апс | Лечение нарушений со стороны печени, желчных путей и поджелудочной железы |
| CN111182915A (zh) | 2017-08-15 | 2020-05-19 | 金德雷德生物科学股份有限公司 | 兽药用IgG Fc变体 |
| DE102017219504A1 (de) | 2017-11-02 | 2019-05-02 | Bayerische Motoren Werke Aktiengesellschaft | Beleuchtungsvorrichtung für ein Kraftfahrzeug |
| KR20200095472A (ko) * | 2017-11-10 | 2020-08-10 | 디펜신 테라퓨틱스 에이피에스 | 조산아에서의 점막 방어 및 장/폐 기능의 성숙화 |
| MX2020005370A (es) * | 2017-11-24 | 2020-10-19 | Defensin Therapeutics Aps | Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas. |
| JP7479381B2 (ja) * | 2019-01-07 | 2024-05-08 | アエスクルス バイオ エーピーエス | 治療または予防に使用するためのディフェンシン断片 |
| CN110447763B (zh) * | 2019-07-05 | 2023-01-20 | 江西农业大学 | 细菌在影响动物瘦肉率和/或脂肪含量中的应用 |
| CN114072071A (zh) * | 2019-07-19 | 2022-02-18 | 华盛顿大学 | 影响人类肠道微生物的组合物和方法 |
| CN111153982B (zh) * | 2020-02-17 | 2022-05-31 | 西北农林科技大学 | 一种反刍动物瘤胃特异抗菌肽defb1及其应用 |
| CN111202752A (zh) * | 2020-02-17 | 2020-05-29 | 上海市内分泌代谢病研究所 | 阿克曼氏菌组合物 |
| CN111635874B (zh) * | 2020-06-05 | 2022-03-18 | 江南大学 | 一株能够调控肠道阿克曼菌属相对丰度的脆弱拟杆菌 |
| KR102363092B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법 |
| KR102363098B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법 |
| CN111938158B (zh) * | 2020-08-18 | 2023-07-07 | 广东弘元普康医疗科技有限公司 | 一种防止肠道Akkermansia muciniphila菌丰度降低的组合物 |
| CN112121152B (zh) * | 2020-09-25 | 2021-06-22 | 南京大学 | 利司那肽在制备抗肿瘤药物中的应用 |
| CR20240137A (es) * | 2021-08-20 | 2024-07-29 | Biocad Joint Stock Co | Método para obtener una cápside de virus adenoasociado modificada |
| KR102740789B1 (ko) * | 2021-10-26 | 2024-12-11 | 가톨릭대학교 산학협력단 | 장내 마이크로바이옴을 이용한 천식의 중증도 및 복부비만 위험도 예측 방법 |
| CN115125167A (zh) * | 2022-06-15 | 2022-09-30 | 上海交通大学医学院附属瑞金医院 | 微生物组合及其用途 |
| CN114874311A (zh) * | 2022-06-20 | 2022-08-09 | 成都施桂行医药科技有限责任公司 | 防御肽及其制备方法和应用 |
| CN116268203B (zh) * | 2023-01-20 | 2024-08-20 | 中国农业大学 | 嗜黏蛋白阿克曼菌膜蛋白Amuc_1100在改善家禽蛋品质中的用途 |
| CN120535656B (zh) * | 2025-05-26 | 2025-12-12 | 中国农业大学 | 一种抗菌重组蛋白及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528107B2 (en) * | 2005-11-30 | 2009-05-05 | Auburn University | Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins |
| WO2007133373A2 (en) * | 2006-05-01 | 2007-11-22 | England Robert L | TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α |
| WO2008115390A2 (en) * | 2007-03-16 | 2008-09-25 | The Hamner Institutes For Health Sciences | Methods of using defensins to treat diabetes |
| US20110311601A1 (en) * | 2010-06-22 | 2011-12-22 | Michael Kleine | Antimicrobial medical devices |
| JP6219277B2 (ja) * | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | 炎症性腸疾患の経口治療 |
| US20130052213A1 (en) * | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
| CN104971343B (zh) * | 2015-07-13 | 2018-02-02 | 韩源平 | 防御素在制备治疗代谢综合征药物方面的应用 |
-
2017
- 2017-01-26 KR KR1020187021406A patent/KR20180121489A/ko not_active Withdrawn
- 2017-01-26 MX MX2018009100A patent/MX2018009100A/es unknown
- 2017-01-26 AU AU2017212534A patent/AU2017212534A1/en not_active Abandoned
- 2017-01-26 JP JP2018557190A patent/JP6890135B2/ja not_active Expired - Fee Related
- 2017-01-26 EP EP17705790.8A patent/EP3407905B1/en active Active
- 2017-01-26 SG SG11201805954WA patent/SG11201805954WA/en unknown
- 2017-01-26 BR BR112018015170-0A patent/BR112018015170A2/pt not_active IP Right Cessation
- 2017-01-26 US US16/072,953 patent/US20190111107A1/en not_active Abandoned
- 2017-01-26 ES ES17705790T patent/ES2871117T3/es active Active
- 2017-01-26 WO PCT/DK2017/050017 patent/WO2017129195A1/en not_active Ceased
- 2017-01-26 RU RU2018129160A patent/RU2738265C2/ru active
- 2017-01-26 CA CA3012711A patent/CA3012711A1/en not_active Abandoned
- 2017-01-26 CN CN201780017713.0A patent/CN108778309A/zh active Pending
-
2018
- 2018-07-06 ZA ZA2018/04515A patent/ZA201804515B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504122A5 (enExample) | ||
| RU2018129160A (ru) | Способы модуляции кишечной микробиоты | |
| US10413593B2 (en) | Co-agonists of the glucagon and GLP-1 receptors | |
| Gupta | Glucagon-like peptide-1 analogues: an overview | |
| US11492385B2 (en) | Long-acting co-agonists of the glucagon and GLP-1 receptors | |
| JP2014526254A5 (enExample) | ||
| CN102389413A (zh) | 用于治疗糖尿病的组合物及其应用 | |
| Kounatidis et al. | Therapeutic potential of GLP-2 analogs in gastrointestinal disorders: current knowledge, nutritional aspects, and future perspectives | |
| KR102019911B1 (ko) | 질병 및 장애 치료용 펩타이드 유사체 | |
| AU2013276610A1 (en) | Exendin-4 peptide analogues | |
| Stonehouse et al. | Emerging incretin-based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors | |
| RU2740913C2 (ru) | Лечение нарушений со стороны печени, желчных путей и поджелудочной железы | |
| JP2019514908A5 (enExample) | ||
| WO2005072056A2 (en) | Hsp therapy in conjunction with a low antigenicity diet | |
| Yamane et al. | Physiology and clinical applications of GIP | |
| EP4419130A1 (en) | Il-4 derived peptides for use in the treatment of obesity | |
| Khalil et al. | A Review on the Strategies of Treatment of Type-2 Diabetes Mellitus: Focus on Vildagliptin | |
| US20200054716A1 (en) | Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies | |
| Zhang et al. | Exendin-4 and Its Derivatives for Diabetes and Obesity: Old Story and New Hope | |
| HK40001163B (en) | Methods for modulating intestinal microbiota | |
| JP2023508347A (ja) | グルカゴン受容体およびｇｌｐ－１受容体のステープルラクタムコアゴニスト | |
| Parmar et al. | Research Journal of Pharmaceutical, Biological and Chemical Sciences | |
| Holcombe et al. | Management of type 2 diabetes: the role of incretin mimetics |